AMLimmunologicphenotypeSA-1prognosisA monoclonal antibody has been raised against a surface membrane antigen present on leukemic myeloblasts. In 52 consecutive patients with acute myeloid leukemia treated in a standardized fashion with intensive chemotherapy the immunologic subclass with respect to this ...
Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBF... Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease ...
13 Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly with azacitidine and gemtuzumab ozogamicin (GO)doi:10.1016/S0145-2126(07)70014-0S. NandJ. GodwinS. SmithK. BartonE. GermanoP. Stiff...
Scientists at St. Jude Children’s Research Hospital have discovered a mutation in pediatric acute myeloid leukemia (AML) that physicians can use to identify patients with a high-risk of relapse. Apaper on the workwas published inBlood Cancer Discovery, a journal of t...
Haploidentical SCT in patients with high risk AML: experience of one center.doi:10.1016/j.clml.2017.07.078Motorin, DmitriyBadaev, RenatZammoeva, DarinaGirshova, LarisaBabenetskaya, DianaIlyina, NatalyaSilina, TatyanaAlexeeva, YuliyaIvanov, Vladimir...
AML Index issued by the Basel Institute of Governance. The domestic list is worth its weight in gold and it is an important tool especially when it comes to the Risk-Based Approach (RBA). As such, the List is required to be revisited. Substantial changes are then brought so as to avoid...
AML policies and procedures in place Third-party documentation Local market reputation through review of media sources In many cases, explicit legal specifications automatically call for EDD. For example, in Europe, under Article 18 of 4AMLD, any business located in a country on the High-Risk Thi...
with high-risk AML Quizartinib tested in patients with high-risk AMLQuizartinib tested in patients with high-risk AMLdoi:10.1038/s41571-018-0061-8Sidaway PeterNature Reviews Clinical Oncology
Detrait MY, Chevallier P, Sobh M, Guillaume T, Thomas X, Morissetet S et al (2011) Outcome of high-risk and refractory AML/MDS patients receiving a FLAMSA sequential chemotherapy regimen followed by reduced-intensity conditioning (RIC) and allogeneic hematopoeitic stem cell transplantation (...
Researchers found that the use offludarabine, high-dosecytarabine, with granulocyte-colony stimulating factor (FLAG) — with or withoutidarubicin(Ida) — resulted in higher remission rates for nonfavorable risk AML patients after one course of induction, compared with standard 7+3 (anthracycline plus...